questionsmedicales.fr
Eucaryotes
Euglénozoaires
Kinetoplastida
Trypanosomatina
Leishmania
Leishmania guyanensis
Leishmania guyanensis : Questions médicales fréquentes
Diagnostic
5
Leishmaniose
Biopsie
Tests sérologiques
Polymerase Chain Reaction
Culture de tissus
Leishmaniose
Lésions cutanées
Ulcères
Démangeaisons
Tests sanguins
Anticorps
Leishmaniose
Historique médical
Zones endémiques
Leishmaniose
Symptômes
5
Lésions cutanées
Ulcères
Nodules
Douleur
Démangeaisons
Lésions cutanées
Fièvre
Symptômes systémiques
Leishmaniose
Guérison spontanée
Traitement
Lésions cutanées
Évolution des lésions
Lésions cutanées
Leishmaniose
Prévention
5
Prévention
Piqûres de phlébotomes
Répulsifs cutanés
Moustiquaires
Piqûres
Leishmaniose
Vêtements
Protection
Piqûres
Vaccins
Leishmania guyanensis
Prévention
Habitat
Phlébotomes
Hygiène environnementale
Traitements
5
Antimoniaux
Amphotéricine B
Médicaments oraux
Complications
Récidives
Traitement
Durée du traitement
Leishmaniose
Gravité
Effets secondaires
Nausées
Douleurs abdominales
Efficacité du traitement
Récidives
Leishmaniose
Complications
5
Complications
Infections secondaires
Cicatrices
Fréquence
Complications
Traitement
Gestion
Soins médicaux
Suivi
Cicatrices
Traitements esthétiques
Leishmaniose
Facteurs de risque
5
Facteurs de risque
Zones endémiques
Phlébotomes
Immunodépression
Risque accru
Leishmaniose
Voyageurs
Zones endémiques
Précautions
Urbanisation
Habitat
Phlébotomes
Conditions climatiques
Prolifération
Phlébotomes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Leishmania guyanensis : Questions médicales les plus fréquentes",
"headline": "Leishmania guyanensis : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Leishmania guyanensis : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-05",
"dateModified": "2026-02-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Leishmania guyanensis"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Leishmania",
"url": "https://questionsmedicales.fr/mesh/D007891",
"about": {
"@type": "MedicalCondition",
"name": "Leishmania",
"code": {
"@type": "MedicalCode",
"code": "D007891",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B01.268.475.868.488"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Leishmania guyanensis",
"alternateName": "Leishmania guyanensis",
"code": {
"@type": "MedicalCode",
"code": "D018334",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mara Lúcia Gomes de Souza",
"url": "https://questionsmedicales.fr/author/Mara%20L%C3%BAcia%20Gomes%20de%20Souza",
"affiliation": {
"@type": "Organization",
"name": "Fundação de Medicina Tropical Dr Heitor Viera Dourado, Manaus, Amazona, Brazil."
}
},
{
"@type": "Person",
"name": "Rajendranath Ramasawmy",
"url": "https://questionsmedicales.fr/author/Rajendranath%20Ramasawmy",
"affiliation": {
"@type": "Organization",
"name": "Fundação de Medicina Tropical Dr Heitor Viera Dourado, Manaus, Amazona, Brazil."
}
},
{
"@type": "Person",
"name": "Tirza Gabrielle Ramos de Mesquita",
"url": "https://questionsmedicales.fr/author/Tirza%20Gabrielle%20Ramos%20de%20Mesquita",
"affiliation": {
"@type": "Organization",
"name": "Fundação de Medicina Tropical Dr Heitor Viera Dourado, Manaus, Amazona, Brazil."
}
},
{
"@type": "Person",
"name": "José do Espírito Santo Junior",
"url": "https://questionsmedicales.fr/author/Jos%C3%A9%20do%20Esp%C3%ADrito%20Santo%20Junior",
"affiliation": {
"@type": "Organization",
"name": "Programa de Pós-Graduação em Imunologia Básica e Aplicada, Instituto de Ciências Biológicas, Universidade Federal do Amazonas, Manaus, Amazonas, Brazil."
}
},
{
"@type": "Person",
"name": "Martin Olivier",
"url": "https://questionsmedicales.fr/author/Martin%20Olivier",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, Microbiology and Immunology, Faculty of Medicine, McGill University, Montréal, QC, Canada; Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre, QC, Canada. Electronic address: martin.olivier@mcgill.ca."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Treatment of cutaneous leishmaniasis with a sequential scheme of pentamidine and tamoxifen in an area with a predominance of Leishmania (Viannia) guyanensis: A randomised, non-inferiority clinical trial.",
"datePublished": "2023-11-08",
"url": "https://questionsmedicales.fr/article/37936525",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/tmi.13943"
}
},
{
"@type": "ScholarlyArticle",
"name": "Variants of CARD8 in Leishmania guyanensis-cutaneous leishmaniasis and influence of the variants genotypes on circulating plasma cytokines IL-1β, TNFα and IL-8.",
"datePublished": "2023-06-05",
"url": "https://questionsmedicales.fr/article/37276232",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pntd.0011416"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immunoregulatory effects of soluble antigens of Leishmania sp. in human lymphocytes in vitro.",
"datePublished": "2024-09-20",
"url": "https://questionsmedicales.fr/article/39319928",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/1519-6984.284001"
}
},
{
"@type": "ScholarlyArticle",
"name": "The protein map of the protozoan parasite Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis and Leishmania (Leishmania) infantum during growth phase transition and temperature stress.",
"datePublished": "2024-01-16",
"url": "https://questionsmedicales.fr/article/38237666",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jprot.2024.105088"
}
},
{
"@type": "ScholarlyArticle",
"name": "Updated estimation of cutaneous leishmaniasis incubation period in French Guiana.",
"datePublished": "2023-06-14",
"url": "https://questionsmedicales.fr/article/37315094",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pntd.0011415"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Eucaryotes",
"item": "https://questionsmedicales.fr/mesh/D056890"
},
{
"@type": "ListItem",
"position": 3,
"name": "Euglénozoaires",
"item": "https://questionsmedicales.fr/mesh/D056898"
},
{
"@type": "ListItem",
"position": 4,
"name": "Kinetoplastida",
"item": "https://questionsmedicales.fr/mesh/D016830"
},
{
"@type": "ListItem",
"position": 5,
"name": "Trypanosomatina",
"item": "https://questionsmedicales.fr/mesh/D014351"
},
{
"@type": "ListItem",
"position": 6,
"name": "Leishmania",
"item": "https://questionsmedicales.fr/mesh/D007891"
},
{
"@type": "ListItem",
"position": 7,
"name": "Leishmania guyanensis",
"item": "https://questionsmedicales.fr/mesh/D018334"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Leishmania guyanensis - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Leishmania guyanensis",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Leishmania guyanensis",
"description": "Comment diagnostiquer une infection par Leishmania guyanensis ?\nQuels tests sont utilisés pour confirmer la leishmaniose ?\nQuels symptômes indiquent une infection par Leishmania guyanensis ?\nPeut-on diagnostiquer la leishmaniose par des tests sanguins ?\nQuelle est l'importance de l'historique médical dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D018334#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Leishmania guyanensis",
"description": "Quels sont les symptômes principaux de la leishmaniose cutanée ?\nLes symptômes de Leishmania guyanensis sont-ils douloureux ?\nY a-t-il des symptômes systémiques associés ?\nLes lésions de Leishmania guyanensis guérissent-elles spontanément ?\nComment évoluent les lésions cutanées ?",
"url": "https://questionsmedicales.fr/mesh/D018334#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Leishmania guyanensis",
"description": "Comment prévenir l'infection par Leishmania guyanensis ?\nLes moustiquaires sont-elles efficaces contre Leishmania ?\nQuels vêtements porter pour se protéger ?\nY a-t-il des vaccins disponibles contre Leishmania guyanensis ?\nComment réduire les habitats des phlébotomes ?",
"url": "https://questionsmedicales.fr/mesh/D018334#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Leishmania guyanensis",
"description": "Quels traitements sont efficaces contre Leishmania guyanensis ?\nLe traitement est-il toujours nécessaire ?\nCombien de temps dure le traitement typique ?\nY a-t-il des effets secondaires aux traitements ?\nLes traitements sont-ils efficaces à 100 % ?",
"url": "https://questionsmedicales.fr/mesh/D018334#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Leishmania guyanensis",
"description": "Quelles complications peuvent survenir avec la leishmaniose ?\nLa leishmaniose peut-elle affecter d'autres organes ?\nLes complications sont-elles fréquentes ?\nComment les complications sont-elles gérées ?\nLes cicatrices de leishmaniose sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D018334#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Leishmania guyanensis",
"description": "Quels sont les principaux facteurs de risque pour Leishmania guyanensis ?\nLes personnes immunodéprimées sont-elles plus à risque ?\nLes voyageurs sont-ils à risque d'infection ?\nL'urbanisation influence-t-elle le risque d'infection ?\nLes conditions climatiques affectent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D018334#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection par Leishmania guyanensis ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par biopsie cutanée ou tests sérologiques spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer la leishmaniose ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests PCR et les cultures de tissus sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une infection par Leishmania guyanensis ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des lésions cutanées, des ulcères et des démangeaisons."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer la leishmaniose par des tests sanguins ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests sérologiques peuvent détecter des anticorps contre le parasite."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de l'historique médical dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique d'exposition à des zones endémiques est crucial pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux de la leishmaniose cutanée ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des lésions cutanées, des ulcères et des nodules."
}
},
{
"@type": "Question",
"name": "Les symptômes de Leishmania guyanensis sont-ils douloureux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les lésions peuvent être douloureuses et provoquer des démangeaisons."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes systémiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes systémiques comme la fièvre peuvent survenir dans certains cas."
}
},
{
"@type": "Question",
"name": "Les lésions de Leishmania guyanensis guérissent-elles spontanément ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines lésions peuvent guérir spontanément, mais un traitement est recommandé."
}
},
{
"@type": "Question",
"name": "Comment évoluent les lésions cutanées ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les lésions peuvent s'étendre et devenir plus profondes si non traitées."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'infection par Leishmania guyanensis ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les piqûres de phlébotomes et utiliser des répulsifs cutanés."
}
},
{
"@type": "Question",
"name": "Les moustiquaires sont-elles efficaces contre Leishmania ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les moustiquaires traitées peuvent réduire le risque de piqûres."
}
},
{
"@type": "Question",
"name": "Quels vêtements porter pour se protéger ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Porter des vêtements longs et de couleur claire aide à prévenir les piqûres."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins disponibles contre Leishmania guyanensis ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin efficace contre cette espèce."
}
},
{
"@type": "Question",
"name": "Comment réduire les habitats des phlébotomes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éliminer les eaux stagnantes et maintenir une bonne hygiène environnementale."
}
},
{
"@type": "Question",
"name": "Quels traitements sont efficaces contre Leishmania guyanensis ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent les antimoniaux, l'amphotéricine B et les médicaments oraux."
}
},
{
"@type": "Question",
"name": "Le traitement est-il toujours nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est recommandé pour éviter des complications et des récidives."
}
},
{
"@type": "Question",
"name": "Combien de temps dure le traitement typique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dure généralement de 20 à 30 jours, selon la gravité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des nausées et des douleurs abdominales peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à 100 % ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements sont généralement efficaces, mais des récidives peuvent se produire."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la leishmaniose ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections secondaires et des cicatrices permanentes."
}
},
{
"@type": "Question",
"name": "La leishmaniose peut-elle affecter d'autres organes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dans certains cas, elle peut affecter le foie et la rate, causant des complications."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares mais peuvent survenir si la maladie n'est pas traitée."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications nécessitent souvent des soins médicaux supplémentaires et un suivi."
}
},
{
"@type": "Question",
"name": "Les cicatrices de leishmaniose sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cicatrices peuvent être permanentes, mais des traitements esthétiques peuvent aider."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour Leishmania guyanensis ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent la vie dans des zones endémiques et l'exposition à des phlébotomes."
}
},
{
"@type": "Question",
"name": "Les personnes immunodéprimées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées courent un risque accru d'infection."
}
},
{
"@type": "Question",
"name": "Les voyageurs sont-ils à risque d'infection ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyageurs dans des zones endémiques doivent prendre des précautions."
}
},
{
"@type": "Question",
"name": "L'urbanisation influence-t-elle le risque d'infection ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'urbanisation peut créer des habitats favorables aux phlébotomes."
}
},
{
"@type": "Question",
"name": "Les conditions climatiques affectent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conditions climatiques chaudes et humides favorisent la prolifération des phlébotomes."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 25/02/2026
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
Affiliations :
Fundação de Medicina Tropical Dr Heitor Viera Dourado, Manaus, Amazona, Brazil.
7 publications dans cette catégorie
Affiliations :
Fundação de Medicina Tropical Dr Heitor Viera Dourado, Manaus, Amazona, Brazil.
Programa de Pós Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil.
Programa de Pós Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas, Manaus, Amazonas, Brazil.
Faculdade de Medicina, Universidade Nilton Lins, Manaus, Amazonas, Brazil.
6 publications dans cette catégorie
Affiliations :
Fundação de Medicina Tropical Dr Heitor Viera Dourado, Manaus, Amazona, Brazil.
Programa de Pós Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil.
5 publications dans cette catégorie
Affiliations :
Programa de Pós-Graduação em Imunologia Básica e Aplicada, Instituto de Ciências Biológicas, Universidade Federal do Amazonas, Manaus, Amazonas, Brazil.
Faculdade de Medicina Nilton Lins, Universidade Nilton Lins, Manaus, Brazil.
Publications dans "Leishmania guyanensis" :
5 publications dans cette catégorie
Affiliations :
Department of Medicine, Microbiology and Immunology, Faculty of Medicine, McGill University, Montréal, QC, Canada; Infectious Diseases and Immunity in Global Health Program, The Research Institute of the McGill University Health Centre, QC, Canada. Electronic address: martin.olivier@mcgill.ca.
Publications dans "Leishmania guyanensis" :
4 publications dans cette catégorie
Affiliations :
Fundação de Medicina Tropical Dr Heitor Viera Dourado, Manaus, Amazona, Brazil.
Programa de Pós Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil.
Publications dans "Leishmania guyanensis" :
4 publications dans cette catégorie
Affiliations :
Fundação de Medicina Tropical Dr Heitor Viera Dourado, Manaus, Amazona, Brazil.
Publications dans "Leishmania guyanensis" :
4 publications dans cette catégorie
Affiliations :
Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
Faculdade de Medicina, Universidade Nilton Lins, Amazonas, Manaus, Brazil.
Publications dans "Leishmania guyanensis" :
4 publications dans cette catégorie
Affiliations :
Department of Parasitology, Faculty of Science, Charles University, Prague, Czech Republic.
Publications dans "Leishmania guyanensis" :
3 publications dans cette catégorie
Affiliations :
Programa de Estudios y Control de Enfermedades Tropicales (PECET), Universidad de Antioquia, Medellín, Colombia.
Publications dans "Leishmania guyanensis" :
3 publications dans cette catégorie
Affiliations :
Facultad de Ciencias Naturales, Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Universidad del Rosario, Bogotá, Colombia.
Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Publications dans "Leishmania guyanensis" :
3 publications dans cette catégorie
Affiliations :
Fundação de Medicina Tropical Dr Heitor Viera Dourado, Manaus, Amazona, Brazil.
Programa de Pós Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas, Manaus, Amazonas, Brazil.
Publications dans "Leishmania guyanensis" :
3 publications dans cette catégorie
Affiliations :
Ministério da Saúde, Secretaria de Vigilância em Saúde, Instituto Evandro Chagas, Belém, PA, Brazil.
Publications dans "Leishmania guyanensis" :
2 publications dans cette catégorie
Affiliations :
Facultad de Ciencias Naturales, Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Universidad del Rosario, Bogotá, Colombia.
Publications dans "Leishmania guyanensis" :
2 publications dans cette catégorie
Affiliations :
Laboratório de Pesquisa em Leishmanioses, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
Publications dans "Leishmania guyanensis" :
2 publications dans cette catégorie
Affiliations :
Fundação de Medicina Tropical Dr Heitor Viera Dourado, Manaus, Amazona, Brazil.
Programa de Pós Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas, Manaus, Amazonas, Brazil.
Publications dans "Leishmania guyanensis" :
2 publications dans cette catégorie
Affiliations :
Fundação de Medicina Tropical Dr Heitor Viera Dourado, Manaus, Amazona, Brazil.
Publications dans "Leishmania guyanensis" :
2 publications dans cette catégorie
Affiliations :
Fundação de Medicina Tropical Dr Heitor Viera Dourado, Manaus, Amazona, Brazil.
Publications dans "Leishmania guyanensis" :
2 publications dans cette catégorie
Affiliations :
Fundação de Medicina Tropical Dr Heitor Viera Dourado, Manaus, Amazona, Brazil.
Programa de Pós Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil.
Publications dans "Leishmania guyanensis" :
2 publications dans cette catégorie
Affiliations :
Fundação Hospitalar de Dermatologia Tropical e Venereologia Alfredo da Matta, Manaus, Brazil.
Publications dans "Leishmania guyanensis" :
To determine whether a combination of a single intramuscular (IM) dose of pentamidine (7 mg/kg) followed by oral tamoxifen 40 mg/day for 20 days is non-inferior to three IM doses of pentamidine 7 mg/k...
Phase II, randomised, controlled, open-label, non-inferiority clinical trial. Primary outcome was the complete healing of the lesions 6 months after starting treatment. Secondary outcomes were healing...
The research was concluded with 49 patients; Leishmania (Viannia) guyanensis was the most frequent species isolated. In the primary outcome, 18 (72%) (95% CI: 52.4%-85.7%) of the 25 patients allocated...
Although a 72% cure rate presented by the combination of tamoxifen and pentamidine was lower than in the control group that achieved a 100% cure, it is still a safe and is a clinically relevant result...
Nucleotide-binding oligomerization domain, leucine-rich repeat-containing protein family (NLR) are intracellular pathogen recognition receptors mediating innate immunity, releasing proinflammatory cyt...
The clinical manifestations of cutaneous leishmaniasis (CL) depend not only on the infecting species involved, but also on the immune response of the individual. Although not yet well understood in hu...
Leishmania parasites cause a spectrum of diseases termed leishmaniasis, which manifests in two main clinical forms, cutaneous and visceral leishmaniasis. Leishmania promastigotes transit from prolifer...
The cutaneous leishmaniasis (CL) incubation period (IP) is defined as the time between parasite inoculation by sandfly bite and the onset of the first CL lesion. IP distribution is difficult to assess...
We estimated CL incubation period distribution using time-to-event models adapted to interval-censored data based on declared date of travels from symptomatic military personnel living in non-endemic ...
A total of 180 patients were included, of which 176 were men (97.8%), with a median age of 26 years. When recorded, the parasite species was always Leishmania guyanensis (31/180, 17.2%). The main peri...
This work suggests that the CL IP distribution in French Guiana is shorter and more restricted than anticipated. As the incidence of CL in FG usually peaks in January and March, these findings suggest...
In the Mediterranean basin, three Leishmania species have been identified: L. infantum, L. major and L. tropica, causing zoonotic visceral leishmaniasis (VL), zoonotic cutaneous leishmaniasis (CL) and...
U937 cells differentiated into macrophage-like cells were infected with L. infantum, L. major and L. tropica for 24h and 48h, and total RNA was extracted. RNA sequencing, performed on an Illumina Nova...
The identification of pathways elicited by parasites causing VL or CL could lead to new therapeutic strategies for leishmaniasis, combining the canonical anti-leishmania compounds with host-directed t...
Cutaneous leishmaniasis is a neglected disease prevalent in tropical countries, and conventional treatment can cause several serious side effects. Photodynamic therapy represents an alternative treatm...
Since 1999, the number of asymptomatic leishmaniasis cases has increased continuously in Thailand, particularly among patients with HIV who are prone to develop symptoms of cutaneous and visceral leis...
In Brazil, Leishmania (Leishmania) infantum is a widely distributed protozoan parasite. The human leishmaniasis caused by this species is often associated with visceral form. Tegumentary leishmaniasis...
Here, we describe two distinct cases of TL with atypical clinical presentations caused by L. (L.) infantum....
Parasites were isolated from cutaneous lesions of the two patients and typed as L. (L.) infantum after sequencing of the ribosomal DNA internal transcribed spacer. The dermotropic L. (L.) infantum iso...
This study addresses the emergence of L. (L.) infantum as a causative agent of cutaneous disease in a visceral leishmaniasis hotspot located in northeast Brazil. The data presented provides novel info...
Leishmaniasis is a relevant disease worldwide due to its presence in many countries and an estimated prevalence of 10 million people. The causative agent of this disease is the obligate intracellular ...